Chemotherapy-induced peripheral neuropathy: Current status and progress.

[1]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[2]  Daniel L. Koller,et al.  Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 , 2015, Clinical Cancer Research.

[3]  A. Höke,et al.  Mechanisms of distal axonal degeneration in peripheral neuropathies , 2015, Neuroscience Letters.

[4]  Yusuke Nakamura,et al.  Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy , 2015, Clinical Cancer Research.

[5]  E. Giovannetti,et al.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future. , 2015, The oncologist.

[6]  E. Gonzalez-Billalabeitia,et al.  Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  P. Dougherty,et al.  Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy. , 2015, Gynecologic oncology.

[8]  Cristina Santos,et al.  Genetic determinants of chronic oxaliplatin‐induced peripheral neurotoxicity: a genome‐wide study replication and meta‐analysis , 2015, Journal of the peripheral nervous system : JPNS.

[9]  Jie J. Zheng,et al.  Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. , 2015, JAMA.

[10]  M. Dolan,et al.  Modeling Chemotherapeutic Neurotoxicity with Human Induced Pluripotent Stem Cell-Derived Neuronal Cells , 2015, PloS one.

[11]  Wardiya Afshar Saber,et al.  Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts , 2014, Nature Neuroscience.

[12]  G. Kimmick,et al.  Breast and ovarian cancer in the older woman. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Dawn L Hershman,et al.  Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Nancy J Cox,et al.  Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. , 2014, Journal of the National Cancer Institute.

[15]  L. Carey,et al.  Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy , 2014, Breast Cancer Research and Treatment.

[16]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[17]  A. Argyriou,et al.  Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature , 2014, Cancer management and research.

[18]  J. Mefford,et al.  Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) , 2014, The Pharmacogenomics Journal.

[19]  M. Koltzenburg,et al.  Chemotherapy‐induced peripheral neurotoxicity: A critical analysis , 2013, CA: a cancer journal for clinicians.

[20]  A. Eschalier,et al.  A Polyamine-Deficient Diet Prevents Oxaliplatin-Induced Acute Cold and Mechanical Hypersensitivity in Rats , 2013, PloS one.

[21]  K. Eggan,et al.  Opportunities and challenges of pluripotent stem cell neurodegenerative disease models , 2013, Nature Neuroscience.

[22]  C. Shapiro,et al.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.

[23]  C. Loprinzi,et al.  A Novel and Selective Poly (ADP-Ribose) Polymerase Inhibitor Ameliorates Chemotherapy-Induced Painful Neuropathy , 2013, PloS one.

[24]  Ivo D. Shterev,et al.  Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy , 2012, Clinical Cancer Research.

[25]  P. Novotny,et al.  Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy , 2012, Cancer.

[26]  A. Windebank,et al.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. , 2012, Neuro-oncology.

[27]  Yusuke Nakamura,et al.  A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 , 2012, Clinical Cancer Research.

[28]  M. Dolan,et al.  Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy , 2012, Clinical Cancer Research.

[29]  Joon-Oh Park,et al.  Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients , 2012, Cancer.

[30]  A. Hoke.  Animal Models of Peripheral Neuropathies , 2012 .

[31]  H. Cohen,et al.  Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  G. Bennett,et al.  Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel , 2012, Neuroscience.

[33]  A. Vingerhoets,et al.  Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients , 2011, Supportive Care in Cancer.

[34]  G. Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. , 2011, The Lancet. Oncology.

[35]  Y. Banno,et al.  The pivotal role of intracellular calcium in oxaliplatin-induced inhibition of neurite outgrowth but not cell death in differentiated PC12 cells. , 2011, Chemical research in toxicology.

[36]  C. Loprinzi,et al.  Chemotherapy‐Induced Peripheral Neuropathy: Prevention and Treatment , 2011, Clinical pharmacology and therapeutics.

[37]  T. Yano,et al.  Prevention of oxaliplatin‐induced mechanical allodynia and neurodegeneration by neurotropin in the rat model , 2011, European journal of pain.

[38]  D. Sargent,et al.  Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. , 2010, Journal of Clinical Oncology.

[39]  A. Khrunin,et al.  Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients , 2010, The Pharmacogenomics Journal.

[40]  G. Cavaletti,et al.  Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. , 2010, European journal of cancer.

[41]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[42]  M. Friedlander,et al.  Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. , 2009, Brain : a journal of neurology.

[43]  Y. Sunada,et al.  Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 , 2009, Supportive Care in Cancer.

[44]  M. Miloso,et al.  Role of MAPKs in platinum-induced neuronal apoptosis. , 2009, Neurotoxicology.

[45]  C. Loprinzi,et al.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. , 2008, European journal of cancer.

[46]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Lothe,et al.  Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study , 2007, Journal of Translational Medicine.

[48]  P. Mantyh,et al.  An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat , 2007, Brain Research.

[49]  A. Höke,et al.  Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration , 2006, Neurobiology of Disease.

[50]  D. Cella,et al.  Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study , 2006, International Journal of Gynecologic Cancer.

[51]  Gary J. Bennett,et al.  Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction , 2006, Pain.

[52]  V. Rusch,et al.  Acupuncture is a feasible treatment for post-thoracotomy pain: results of a prospective pilot trial , 2006, BMC anesthesiology.

[53]  F. Lieberman,et al.  Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. , 2006, Seminars in oncology.

[54]  Giampietro Gasparini,et al.  Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study , 2006, BMC cancer.

[55]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  K. Hoang-Xuan,et al.  The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. , 2005, European journal of cancer.

[57]  A. Knight,et al.  Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity , 2005, Neurobiology of Disease.

[58]  J. Heimans,et al.  Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. , 2004, Anticancer research.

[59]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[60]  M. Carré,et al.  Tubulin Is an Inherent Component of Mitochondrial Membranes That Interacts with the Voltage-dependent Anion Channel* , 2002, The Journal of Biological Chemistry.

[61]  J. Skepper,et al.  Paclitaxel Affects Cytosolic Calcium Signals by Opening the Mitochondrial Permeability Transition Pore* , 2002, The Journal of Biological Chemistry.

[62]  M. Rich,et al.  The WldS protein protects against axonal degeneration: A model of gene therapy for peripheral neuropathy , 2001, Annals of neurology.

[63]  A. Windebank,et al.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. , 1998, The Journal of clinical investigation.

[64]  G. Cavaletti,et al.  Experimental Peripheral Neuropathy Induced in Adult Rats by Repeated Intraperitoneal Administration of Taxol , 1995, Experimental Neurology.

[65]  R. Donehower,et al.  Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies , 1994, Annals of neurology.

[66]  J. Arezzo,et al.  Nerve growth factor prevents toxic neuropathy in mice , 1991, Annals of neurology.

[67]  T. Postma,et al.  Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  Luís Alexandre Pedro de Freitas,et al.  Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. , 2013, Neurotoxicology.

[69]  A. Höke.  Animal Models of Peripheral Neuropathies , 2012, Neurotherapeutics.

[70]  J. Thigpen.  Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma , 2006 .

[71]  A. Argyriou,et al.  Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. , 2005, Journal of neurology.

[72]  H. Hartung,et al.  Chemotherapy-induced peripheral neuropathy , 2002, Journal of Neurology.